TED-A9 is high-purity ventral midbrain dopaminergic progenitor cells derived from human embryonic stem cells (hESCs) under rigorous GMP conditions All 12 participants in Phase 1/2a were administered ...
SEOUL, SOUTH KOREA, July 21, 2025 (GLOBE NEWSWIRE) -- S.BIOMEDICS announced encouraging one-year post-transplant results from Phase 1/2a clinical trial evaluating A9-DPC cell therapy for Parkinson's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback